Trial NCT05177796

View at ClinicalTrials.gov 
Org. Study IDs: 2020-0715
Secondary IDs: 2020-0715 NCI-2021-13704

Last trial update was posted on 2023-07-28

MeSH Interventions

Albumin-Bound Paclitaxel Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Carboplatin Cyclophosphamide Daunorubicin Doxorubicin Immunoglobulins Liposomal doxorubicin Paclitaxel Panitumumab Pembrolizumab

MeSH Conditions

Breast Neoplasms Carcinoma Inflammatory Breast Neoplasms

Other Conditions

Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Breast Inflammatory Carcinoma Invasive Breast Carcinoma Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma

Stopping Reasons

0 participants recruited

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID